Amend Title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.

Rudy Yakym III · Indiana · Republican

policy impact 0.45 specificity 0.82 extraction confidence 78%

Commitment kind: action. Promised action: Amend title XI of the Social Security Act to change Medicare price negotiation eligibility timing for biosimilar biological products.. Promised outcome: Alter when biosimilar biological products are eligible for price negotiations under the Medicare program.. Deadline: unknown; not assumed expired. Federal House context; Rudy Yakym was listed as a cosponsor of H.R. 10628 in the Congressional Record on September 28, 2026.

Contest this claim

Occurrences

By Mr. LANGWORTHY (for himself, Mr. A UCHINCLOSS, Mr. JOYCE of Penn- sylvania, Ms. S A´ NCHEZ, Mr. P ETERS, Mr. YAKYM, Mr. M ORAN, Mr. M ULLIN, and Mr. PANETTA): H.R. 10628. A bill to amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price ne- gotiations under the Medicare program; to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means

Yakym was listed as a cosponsor of H.R. 10628, a bill to amend the Social Security Act regarding when biosimilar biological products become eligible for Medicare price negotiations.

CREC-2026-09-28-pt1-PgH6010-2.pdf
primary · other · model gpt-5.5

Evidence

verified · Source version 79469 · locator 5479

H.R. 10628. A bill to amend title XI of the Social Security Act to alter when biosimilar biological products are eligible

Fetched verbatim passage. AI summary (separate from source): The Congressional Record shows H.R. 10628 was introduced and referred to House committees, indicating legislative effort but not enactment.

unresolved same_term A for effort

CREC-2026-09-28-pt1-PgH6010-2.pdf
primary · model gpt-5.5 · confidence 86%

Contest this evidence item

verified · Source version 79470 · locator 3964

The legislation is also co-led by Reps. Jake Auchincloss (D-MA), John Joyce (R-PA), Linda Sánchez (D-CA), Scott Peters (D-CA), Rudy Yakym (R-IN)

Fetched verbatim passage. AI summary (separate from source): A captured official House press release within the lookback window names Rudy Yakym as a co-lead of the bill, documenting effort, while describing the measure prospectively as legislation that would change Medicare biosimilar delay rules.

unresolved same_term A for effort

Congressman Langworthy Introduces Bipartisan Biosimilars Access & Affordability Act — Nicholas A. Langworthy
archival · model gpt-5.5 · confidence 82%

Contest this evidence item

Assessments

Public state: pending As of 2026-10-04 · verified · . Original AI recommendation (not independently established): unresolved. unknown A for effort

Verified evidence shows H.R. 10628 was introduced/referred and that Rudy Yakym was a co-lead, documenting material legislative effort. No verified passage shows Title XI was amended, the bill was enacted, or the promised Medicare biosimilar negotiation timing change became law by 2026-10-04. With no documented deadline expired, the attempt does not establish delivery or partial outcome.

provider codex_cli · model gpt-5.5 · confidence 88%